Autoimmune condition psoriasis is characterized by silvery red, flaky lesions. As one ages, it occurs more frequently and frequently. It is an autoimmune disease with a genetic component, but the immunological dysfunction that results positions T-cells at the centre of immunogenetic mechanisms. Psoriasis affects approximately one-fourth of the global population. The clinical diagnosis of psoriasis is primarily based on the patient's unique medical history and physical exam findings. Therapies for psoriasis management are based on the severity of the condition. The most common treatment for psoriasis is topical therapy employing standard dosage forms with minimal adverse effects. Biological therapy was also proposed as an alternative to conventional treatment for certain types, while nano formulation has emerged as a revolutionary advance over the status quo. The use of nanocarriers in psoriasis treatment is a relatively recent innovation. Using nanocarrier-based drug delivery systems allows for targeted medication delivery with improved safety and efficacy. Treatments for psoriasis frequently employ nanocarriers like liposomes, nanostructured lipid nanoparticles, niosomes, and nano emulsions. Increased patient compliance, targeted medication administration, and enhanced safety and efficacy have all contributed to the rise in popularity of nanocarriers. Therefore, the objective of this thesis is to enhance psoriasis treatment by developing a niosomal gel. As a niosomal drug delivery system, the new niosomal gel is demonstrated to be an enhanced method of treating psoriasis with minimal adverse effects. Given that psoriasis is an autoimmune disorder, the use of nanocarriers in conjunction with immunosuppressive medication may be beneficial. Tacrolimus represents an innovative new approach to treating this condition. Improving treatment efficacy necessitates careful consideration of the formulation and dosage of medication fractions. The incorporation of nanotechnology into medication localization and topical targeted administrations bodes well for the creation of nanocarriers for dermatological applications. In conclusion, the optimal treatment for psoriasis will necessitate the development of trustworthy, innocuous nanocarrier technologies. Incorporating the current orally administered drug moiety into nanocarriers for topical distribution would enhance therapeutic payload while decreasing adverse effects, resulting in a more effective treatment for psoriasis.